IBJNews

Genetic testing could spur Erbitux drug sales

Back to TopCommentsE-mailPrintBookmark and Share

Genetic screening to predict which bowel cancer patients will benefit from Eli Lilly and Co.'s tumor- fighting drug Erbitux is becoming more common, according to the Indianapolis-based company's overseas partner, Merck KGaA, while citing a survey that may point to broader use of the treatment.

At least 42 percent of metastatic colorectal cancer patients had been tested early last year for a gene that can predict whether Erbitux will help them, said Oliver Kisker, Merck’s head of cancer clinical development. Testing rates reached 60 percent by the end of 2009, Kisker told German magazine Wirtschaftswoche this month. Screening rates rose further this year, he said Monday, while declining to confirm the Wirtschaftswoche report.

Merck is counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer after European regulators refused to widen approval of the drug to lung cancer patients last year. Research has shown the medicine is more likely to be effective in colorectal cancer patients without a mutated version of the gene. Use of the test spread from 2.5 percent of patients in 2008, the Merck survey found.

“This is amazing,” Kisker said in a telephone interview. The increase is “a very important indicator to us that this treatment now becomes, at least for many areas, part of the standard treatment.”

The survey results through early last year will be presented Tuesday at the American Society of Clinical Oncology meeting in Chicago. Results through early 2010 will be presented at the World Congress on Gastrointestinal Cancer in June, Kisker said.

Erbitux competes with Roche Holding AG’s Avastin and with Amgen Inc.’s Vectibix. Of the 42 percent of patients tested for K-ras in early 2009, 44 percent were treated with the Lilly drug, according to the survey. Almost a quarter of physicians use the genetic screening as a standard part of the diagnostic procedure for metastatic colorectal cancer, Merck said.

The company surveyed 1,254 physicians in Asia, Europe and Latin America. Merck, which isn’t related to U.S. drugmaker Merck & Co., sells Erbitux outside the U.S. and Canada. Lilly and Bristol-Myers Squibb Co. market the medicine in the U.S.

Merck reported $856 million in Erbitux sales last year. The drugmaker’s oncology program suffered twin setbacks in the past 12 months, as European regulators rejected Erbitux in lung cancer and U.S. regulators placed trials of its therapeutic cancer vaccine Stimuvax on hold in March after a patient developed a brain infection while taking it.

Merck remains in talks with the Food and Drug Administration about the halted Stimuvax trials, Kisker said. He declined to say when the discussions would finish or what kind of information the regulator requested.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. In reality, Lilly is maintaining profit by cutting costs such as Indiana/US citizen IT workers by a significant amount with their Tata Indian consulting connection, increasing Indian H1B's at Lillys Indiana locations significantly and offshoring to India high paying Indiana jobs to cut costs and increase profit at the expense of U.S. workers.

  2. I think perhaps there is legal precedence here in that the laws were intended for family farms, not pig processing plants on a huge scale. There has to be a way to squash this judges judgment and overrule her dumb judgement. Perhaps she should be required to live in one of those neighbors houses for a month next to the farm to see how she likes it. She is there to protect the people, not the corporations.

  3. http://www.omafra.gov.on.ca/english/engineer/facts/03-111.htm Corporate farms are not farms, they are indeed factories on a huge scale. The amount of waste and unhealthy smells are environmentally unsafe. If they want to do this, they should be forced to buy a boundary around their farm at a premium price to the homeowners and landowners that have to eat, sleep, and live in a cesspool of pig smells. Imagine living in a house that smells like a restroom all the time. Does the state really believe they should take the side of these corporate farms and not protect Indiana citizens. Perhaps justifiable they should force all the management of the farms to live on the farm itself and not live probably far away from there. Would be interesting to investigate the housing locations of those working at and managing the corporate farms.

  4. downtown in the same area as O'malia's. 350 E New York. Not sure that another one could survive. I agree a Target is needed d'town. Downtown Philly even had a 3 story Kmart for its downtown residents.

  5. Indy-area residents... most of you have no idea how AMAZING Aurelio's is. South of Chicago was a cool pizza place... but it pales in comparison to the heavenly thin crust Aurelio's pizza. Their deep dish is pretty good too. My waistline is expanding just thinking about this!

ADVERTISEMENT